Medtronic plc (MDT) : Zacks Investment Research ranks Medtronic plc (MDT) as 3, which is a Hold recommendation. 11 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 2 other analysts are mildly bullish on the stock and favor a Buy. 1 more believe that the stock has more downside risks, hence they propose a Strong Sell. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 19 research analysts is 1.82, which indicates as a Buy.
Medtronic plc (MDT) has been rated by 14 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $104 and the lowest price target forecast is $56. The average forecast of all the analysts is $89.39 and the expected standard deviation is $11.4.
Shares of Medtronic plc rose by 0.61% in the last five trading days and 1.01% for the last 4 weeks. Medtronic plc is up 9.01% in the last 3-month period. Year-to-Date the stock performance stands at 15.29%. Medtronic plc (NYSE:MDT): stock turned positive on Tuesday. Though the stock opened at $87.78, the bulls momentum made the stock top out at $88.65 level for the day. The stock recorded a low of $87.6193 and closed the trading day at $87.8, in the green by 0.55%. The total traded volume for the day was 3,389,799. The stock had closed at $87.32 in the previous days trading.
Medtronic plc (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. Medtronic, Inc. is a subsidiary of the Company.